Denemek ALTIN - Özgür
Harnessing data analytics to propel drug discovery and development in 2025
Express Pharma
|December 2024
As the pharma landscape evolves, data analytics will be at the forefront of drug discovery and development, transforming traditional methods. By leveraging data-driven insights, companies can expedite R&D, optimise clinical trials, and personalise treatments, bringing life-saving therapies to market more efficiently, explains Biju Davis, SVP, Engineering, Model N

In 2025, pharmaceutical innovation is in a race against time-each day lost in drug development could mean lives unaltered or unextended. As the demand for quicker, more precise medical solutions intensifies, data analytics has emerged not just as a powerful tool but as a lifeline, reshaping the way we discover, test, and deliver lifesaving treatments. With costs soaring up to $2 billion and development spanning more than a decade, as detailed by a Deloitte 2023 report, the stakes have never been higher, and the role of data-driven insights has never been clearer.
The rising need for data-driven insights in pharma
Globally, healthcare generates approximately 80 per cent of the world's data, with the volume expected to grow at a compound annual growth rate (CAGR) of 36 per cent through 2025. India's biotechnology sector has grown to over $130 billion in 2024 and is projected to reach $300 billion by 2030. The significant growth highlights the immense potential in harnessing data analytics to optimise drug discovery, particularly as clinical trials and R&D investments expand to meet both domestic and global demand. This surge in patient health data, clinical research findings, and real-world evidence presents unprecedented opportunities for breakthroughs, but it also underscores the limitations of traditional methods.
Data analytics solutions, through predictive models and deep learning, enable pharma companies to leverage this wealth of information, offering visibility into emerging health trends, patient outcomes, and clinical success indicators. The insights derived reveal critical details about disease progression, treatment efficacy, and demographic-specific responses, allowing researchers to make well-informed, real-time decisions. Data analytics, thus, has become central to producing the insights necessary to thrive in today's high-stakes pharma landscape.
Bu hikaye Express Pharma dergisinin December 2024 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Express Pharma'den DAHA FAZLA HİKAYE

Express Pharma
Flexotherm Heating Tapes & Cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
October 2025

Express Pharma
DRIVING INDIA'S INNOVATION EDGE
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership
16 mins
October 2025

Express Pharma
Al compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations
7 mins
October 2025

Express Pharma
PRIME NEO: New age doors from Gandhi Automation
Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.
1 mins
October 2025

Express Pharma
Unani Medicine: At crossroads of tradition and modernity
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
7 mins
October 2025

Express Pharma
Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand
The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.
1 min
October 2025

Express Pharma
Sustainable packaging with Romaco and Liveo Research
Recycable blister packs
3 mins
October 2025

Express Pharma
With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here
As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.
3 mins
October 2025

Express Pharma
Cell therapy's next chapter: Industry embraces in-vivo innovation
Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases
4 mins
October 2025

Express Pharma
Research misconduct ...can delay meaningful and reliable discoveries
Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions
6 mins
October 2025
Listen
Translate
Change font size